Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Gut Microbiota and Autoimmune Diseases: A Charming Real World Together with Probiotics

Author(s): Andrea Piccioni, Sara Cicchinelli*, Federico Valletta, Giulio De Luca, Yaroslava Longhitano, Marcello Candelli, Veronica Ojetti, Francesco Sardeo, Simone Navarra, Marcello Covino and Francesco Franceschi

Volume 29, Issue 18, 2022

Published on: 10 January, 2022

Page: [3147 - 3159] Pages: 13

DOI: 10.2174/0929867328666210922161913

Price: $65

Abstract

Background: The role of gut microbiota in human disease is fascinating for hundreds of researchers worldwide. Many works have highlighted that gut microbiota modulates the immune system and that its disruption can trigger autoimmune and inflammatory immune-mediated diseases. Probiotics are able to positively modify microbiota composition.

Objective: The aim of this review is to report the most important findings regarding the effects of probiotics administration in the most common autoimmune disease and inflammatory immune-mediated diseases.

Methods: Literature research was performed in PubMed, Google Scholar, and Medline, as well as in specific journal websites using the keywords: “autoimmunity”, “microbiota”, and “probiotics”. The article selection has been made independently by three authors, and controversies have been solved by a fourth researcher. Only English-language articles were included and preference was given to clinical trials, meta-analysis, and case series. After the review process, 68 articles have been considered.

Results: Relying on this evidence, many studies have investigated the potential of probiotics in restoring gut eubiosis, thus affecting pathogenesis, clinical manifestations, and course of these pathologies. Even in the light of few and sometimes contradictory studies, physicians should start to consider these preliminary findings when approaching patients suffering from autoimmune disease. After an accurate case-by-case evaluation of potential candidates, probiotics might be introduced besides the standard therapeutic plan as supportive measures.

Keywords: Probiotics, microbiota, dysbiosis, eubiosis, autoimmunity, immune-mediated diseases.

« Previous Next »
[1]
Belkaid, Y.; Hand, T.W. Role of the microbiota in immunity and inflammation. Cell, 2014, 157(1), 121-141.
[http://dx.doi.org/10.1016/j.cell.2014.03.011] [PMID: 24679531]
[2]
Mu, Q.; Kirby, J.; Reilly, C.M.; Luo, X.M. Leaky gut as a danger signal for autoimmune diseases. Front. Immunol., 2017, 8, 598.
[http://dx.doi.org/10.3389/fimmu.2017.00598] [PMID: 28588585]
[3]
Weinstock, J.V.; Summers, R.; Elliott, D.E. Helminths and harmony. Gut, 2004, 53(1), 7-9.
[http://dx.doi.org/10.1136/gut.53.1.7] [PMID: 14684567]
[4]
Blaser, M.J.; Falkow, S. What are the consequences of the disappearing human microbiota? Nat. Rev. Microbiol., 2009, 7(12), 887-894.
[http://dx.doi.org/10.1038/nrmicro2245] [PMID: 19898491]
[5]
Johnston, C.J.; McSorley, H.J.; Anderton, S.M.; Wigmore, S.J.; Maizels, R.M. Helminths and immunological tolerance. Transplantation, 2014, 97(2), 127-132. Erratum in. Transplantation, 2014, 98(6), e67.
[6]
Zhang, X.; Borbet, T.C.; Fallegger, A.; Wipperman, M.F.; Blaser, M.J.; Müller, A. An antibiotic-impacted microbiota compromises the development of colonic regulatory t cells and predisposes to dysregulated immune responses. MBio, 2021, 12(1), e03335-e20.
[http://dx.doi.org/10.1128/mBio.03335-20] [PMID: 33531385]
[7]
Macpherson, A.J.; Uhr, T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science, 2004, 303(5664), 1662-1665.
[http://dx.doi.org/10.1126/science.1091334] [PMID: 15016999]
[8]
Ivanov, I.I. Frutos, Rde.L.; Manel, N.; Yoshinaga, K.; Rifkin, D.B.; Sartor, R.B.; Finlay, B.B.; Littman, D.R. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe, 2008, 4(4), 337-349.
[http://dx.doi.org/10.1016/j.chom.2008.09.009] [PMID: 18854238]
[9]
Gaboriau-Routhiau, V.; Rakotobe, S.; Lécuyer, E.; Mulder, I.; Lan, A.; Bridonneau, C.; Rochet, V.; Pisi, A.; De Paepe, M.; Brandi, G.; Eberl, G.; Snel, J.; Kelly, D.; Cerf-Bensussan, N. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity, 2009, 31(4), 677-689.
[http://dx.doi.org/10.1016/j.immuni.2009.08.020] [PMID: 19833089]
[10]
Fagarasan, S.; Kawamoto, S.; Kanagawa, O.; Suzuki, K. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu. Rev. Immunol., 2010, 28, 243-273.
[http://dx.doi.org/10.1146/annurev-immunol-030409-101314] [PMID: 20192805]
[11]
Geuking, M.B.; Cahenzli, J.; Lawson, M.A.; Ng, D.C.; Slack, E.; Hapfelmeier, S.; McCoy, K.D.; Macpherson, A.J. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity, 2011, 34(5), 794-806.
[http://dx.doi.org/10.1016/j.immuni.2011.03.021] [PMID: 21596591]
[12]
Shaw, M.H.; Kamada, N.; Kim, Y.G.; Núñez, G. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J. Exp. Med., 2012, 209(2), 251-258.
[http://dx.doi.org/10.1084/jem.20111703] [PMID: 22291094]
[13]
Wu, H.J.; Wu, E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes, 2012, 3(1), 4-14.
[http://dx.doi.org/10.4161/gmic.19320] [PMID: 22356853]
[14]
Rosser, E.C.; Mauri, C. A clinical update on the significance of the gut microbiota in systemic autoimmunity. J. Autoimmun., 2016, 74, 85-93.
[http://dx.doi.org/10.1016/j.jaut.2016.06.009] [PMID: 27481556]
[15]
Lerner, A.; Aminov, R.; Matthias, T. Dysbiosis may trigger autoimmune diseases via inappropriate post-translational modification of host proteins. Front. Microbiol., 2016, 7, 84.
[http://dx.doi.org/10.3389/fmicb.2016.00084] [PMID: 26903965]
[16]
Gareau, M.G.; Sherman, P.M.; Walker, W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat. Rev. Gastroenterol. Hepatol., 2010, 7(9), 503-514.
[http://dx.doi.org/10.1038/nrgastro.2010.117] [PMID: 20664519]
[17]
de Oliveira, G.L.V.; Leite, A.Z.; Higuchi, B.S.; Gonzaga, M.I.; Mariano, V.S. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology, 2017, 152(1), 1-12.
[http://dx.doi.org/10.1111/imm.12765] [PMID: 28556916]
[18]
Bron, P.A.; Kleerebezem, M.; Brummer, R.J.; Cani, P.D.; Mercenier, A.; MacDonald, T.T.; Garcia-Ródenas, C.L.; Wells, J.M. Can probiotics modulate human disease by impacting intestinal barrier function? Br. J. Nutr., 2017, 117(1), 93-107.
[http://dx.doi.org/10.1017/S0007114516004037] [PMID: 28102115]
[19]
Saez-Lara, M.J.; Gomez-Llorente, C.; Plaza-Diaz, J.; Gil, A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. BioMed Res. Int., 2015, 2015, 505878.
[http://dx.doi.org/10.1155/2015/505878] [PMID: 25793197]
[20]
de Kivit, S.; Tobin, M.C.; Forsyth, C.B.; Keshavarzian, A.; Landay, A.L. Regulation of intestinal immune responses through TLR activation: implications for pro- and prebiotics. Front. Immunol., 2014, 5, 60.
[http://dx.doi.org/10.3389/fimmu.2014.00060] [PMID: 24600450]
[21]
Kim, N.; Kunisawa, J.; Kweon, M.N.; Eog Ji, G.; Kiyono, H. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin. Immunol., 2007, 123(1), 30-39.
[http://dx.doi.org/10.1016/j.clim.2006.11.005] [PMID: 17218154]
[22]
Zeuthen, L.H.; Fink, L.N.; Frøkiaer, H. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived Lactobacilli and Bifidobacteria in dendritic cells. Immunology, 2008, 124(4), 489-502.
[http://dx.doi.org/10.1111/j.1365-2567.2007.02800.x] [PMID: 18217947]
[23]
Ishikawa, H.; Akedo, I.; Umesaki, Y.; Tanaka, R.; Imaoka, A.; Otani, T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr., 2003, 22(1), 56-63.
[http://dx.doi.org/10.1080/07315724.2003.10719276] [PMID: 12569115]
[24]
Kato, K.; Mizuno, S.; Umesaki, Y.; Ishii, Y.; Sugitani, M.; Imaoka, A.; Otsuka, M.; Hasunuma, O.; Kurihara, R.; Iwasaki, A.; Arakawa, Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther., 2004, 20(10), 1133-1141.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02268.x] [PMID: 15569116]
[25]
Tursi, A.; Brandimarte, G.; Papa, A.; Giglio, A.; Elisei, W.; Giorgetti, G.M.; Forti, G.; Morini, S.; Hassan, C.; Pistoia, M.A.; Modeo, M.E.; Rodino’, S.; D’Amico, T.; Sebkova, L.; Sacca’, N.; Di Giulio, E.; Luzza, F.; Imeneo, M.; Larussa, T.; Di Rosa, S.; Annese, V.; Danese, S.; Gasbarrini, A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 2010, 105(10), 2218-2227.
[http://dx.doi.org/10.1038/ajg.2010.218] [PMID: 20517305]
[26]
Wang, F.; Yin, Q.; Chen, L.; Davis, M.M. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc. Natl. Acad. Sci. USA, 2018, 115(1), 157-161.
[http://dx.doi.org/10.1073/pnas.1712901115] [PMID: 29255057]
[27]
Wang, T.; Zheng, N.; Luo, Q.; Jiang, L.; He, B.; Yuan, X.; Shen, L. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front. Immunol., 2019, 10, 1235.
[http://dx.doi.org/10.3389/fimmu.2019.01235] [PMID: 31214189]
[28]
Olivares, M.; Neef, A.; Castillejo, G.; Palma, G.D.; Varea, V.; Capilla, A.; Palau, F.; Nova, E.; Marcos, A.; Polanco, I.; Ribes-Koninckx, C.; Ortigosa, L.; Izquierdo, L.; Sanz, Y. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut, 2015, 64(3), 406-417.
[http://dx.doi.org/10.1136/gutjnl-2014-306931] [PMID: 24939571]
[29]
Pozo-Rubio, T.; de Palma, G.; Mujico, J.R.; Olivares, M.; Marcos, A.; Acuña, M.D.; Polanco, I.; Sanz, Y.; Nova, E. Influence of early environmental factors on lymphocyte subsets and gut microbiota in infants at risk of celiac disease; the PROFICEL study. Nutr. Hosp., 2013, 28(2), 464-473.
[PMID: 23822699]
[30]
Canova, C.; Zabeo, V.; Pitter, G.; Romor, P.; Baldovin, T.; Zanotti, R.; Simonato, L. Association of maternal education, early infections, and antibiotic use with celiac disease: a population-based birth cohort study in northeastern Italy. Am. J. Epidemiol., 2014, 180(1), 76-85.
[http://dx.doi.org/10.1093/aje/kwu101] [PMID: 24853109]
[31]
Cinova, J.; De Palma, G.; Stepankova, R.; Kofronova, O.; Kverka, M.; Sanz, Y.; Tuckova, L. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PLoS One, 2011, 6(1), e16169.
[http://dx.doi.org/10.1371/journal.pone.0016169] [PMID: 21249146]
[32]
Laparra, J.M.; Sanz, Y. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J. Cell. Biochem., 2010, 109(4), 801-807.
[PMID: 20052669]
[33]
Laparra, J.M.; Olivares, M.; Gallina, O.; Sanz, Y. Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. PLoS One, 2012, 7(2), e30744.
[http://dx.doi.org/10.1371/journal.pone.0030744] [PMID: 22348021]
[34]
Olivares, M.; Laparra, M.; Sanz, Y. Oral administration of Bifidobacterium longum CECT 7347 modulates jejunal proteome in an in vivo gliadin-induced enteropathy animal model. J. Proteomics, 2012, 77, 310-320.
[http://dx.doi.org/10.1016/j.jprot.2012.09.005] [PMID: 23023000]
[35]
Olivares, M.; Castillejo, G.; Varea, V.; Sanz, Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br. J. Nutr., 2014, 112(1), 30-40.
[http://dx.doi.org/10.1017/S0007114514000609] [PMID: 24774670]
[36]
Klemenak, M.; Dolinšek, J.; Langerholc, T.; Di Gioia, D.; Mičetić-Turk, D. Administration of bifidobacterium breve decreases the production of TNF-α in children with celiac disease. Dig. Dis. Sci., 2015, 60(11), 3386-3392.
[http://dx.doi.org/10.1007/s10620-015-3769-7] [PMID: 26134988]
[37]
Smecuol, E.; Hwang, H.J.; Sugai, E.; Corso, L.; Cherñavsky, A.C.; Bellavite, F.P.; González, A.; Vodánovich, F.; Moreno, M.L.; Vázquez, H.; Lozano, G.; Niveloni, S.; Mazure, R.; Meddings, J.; Mauriño, E.; Bai, J.C. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J. Clin. Gastroenterol., 2013, 47(2), 139-147.
[http://dx.doi.org/10.1097/MCG.0b013e31827759ac] [PMID: 23314670]
[38]
D’Arienzo, R.; Maurano, F.; Luongo, D.; Mazzarella, G.; Stefanile, R.; Troncone, R.; Auricchio, S.; Ricca, E.; David, C.; Rossi, M. Adjuvant effect of Lactobacillus casei in a mouse model of gluten sensitivity. Immunol. Lett., 2008, 119(1-2), 78-83.
[http://dx.doi.org/10.1016/j.imlet.2008.04.006] [PMID: 18547649]
[39]
D’Arienzo, R.; Stefanile, R.; Maurano, F.; Mazzarella, G.; Ricca, E.; Troncone, R.; Auricchio, S.; Rossi, M. Immunomodulatory effects of Lactobacillus casei administration in a mouse model of gliadin-sensitive enteropathy. Scand. J. Immunol., 2011, 74(4), 335-341.
[http://dx.doi.org/10.1111/j.1365-3083.2011.02582.x] [PMID: 21615450]
[40]
Papista, C.; Gerakopoulos, V.; Kourelis, A.; Sounidaki, M.; Kontana, A.; Berthelot, L.; Moura, I.C.; Monteiro, R.C.; Yiangou, M. Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics. Lab. Invest., 2012, 92(4), 625-635.
[http://dx.doi.org/10.1038/labinvest.2012.13] [PMID: 22330344]
[41]
Kasper, L.H.; Shoemaker, J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology, 2010, 74(1)(Suppl. 1), S2-S8.
[http://dx.doi.org/10.1212/WNL.0b013e3181c97c8f] [PMID: 20038759]
[42]
Goverman, J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol., 2009, 9(6), 393-407.
[http://dx.doi.org/10.1038/nri2550] [PMID: 19444307]
[43]
Wekerle, H. Lessons from multiple sclerosis: models, concepts, observations. Ann. Rheum. Dis., 2008, 67(1)(Suppl. 3), iii56-iii60.
[http://dx.doi.org/10.1136/ard.2008.098020] [PMID: 19022815]
[44]
Ochoa-Repáraz, J.; Mielcarz, D.W.; Ditrio, L.E.; Burroughs, A.R.; Begum-Haque, S.; Dasgupta, S.; Kasper, D.L.; Kasper, L.H. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J. Immunol., 2010, 185(7), 4101-4108.
[http://dx.doi.org/10.4049/jimmunol.1001443] [PMID: 20817872]
[45]
Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M.; Fugger, L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol., 2008, 172(1), 146-155.
[http://dx.doi.org/10.2353/ajpath.2008.070690] [PMID: 18156204]
[46]
Lavasani, S.; Dzhambazov, B.; Nouri, M.; Fåk, F.; Buske, S.; Molin, G.; Thorlacius, H.; Alenfall, J.; Jeppsson, B.; Weström, B. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One, 2010, 5(2), e9009.
[http://dx.doi.org/10.1371/journal.pone.0009009] [PMID: 20126401]
[47]
Ochoa-Repáraz, J.; Mielcarz, D.W.; Wang, Y.; Begum-Haque, S.; Dasgupta, S.; Kasper, D.L.; Kasper, L.H. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol., 2010, 3(5), 487-495.
[http://dx.doi.org/10.1038/mi.2010.29] [PMID: 20531465]
[48]
Takata, K.; Kinoshita, M.; Okuno, T.; Moriya, M.; Kohda, T.; Honorat, J.A.; Sugimoto, T.; Kumanogoh, A.; Kayama, H.; Takeda, K.; Sakoda, S.; Nakatsuji, Y. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS One, 2011, 6(11), e27644.
[http://dx.doi.org/10.1371/journal.pone.0027644] [PMID: 22110705]
[49]
Kouchaki, E.; Tamtaji, O.R.; Salami, M.; Bahmani, F.; Daneshvar Kakhaki, R.; Akbari, E.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin. Nutr., 2017, 36(5), 1245-1249.
[http://dx.doi.org/10.1016/j.clnu.2016.08.015] [PMID: 27669638]
[50]
Kieseier, B.C.; Lehmann, H.C.; Meyer Zu Hörste, G. Autoimmune diseases of the peripheral nervous system. Autoimmun. Rev., 2012, 11(3), 191-195.
[http://dx.doi.org/10.1016/j.autrev.2011.05.011] [PMID: 21621007]
[51]
Kaldor, J.; Speed, B.R. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br. Med. J. (Clin. Res. Ed.), 1984, 288(6434), 1867-1870.
[http://dx.doi.org/10.1136/bmj.288.6434.1867] [PMID: 6428580]
[52]
Allos, B.M. Association between Campylobacter infection and Guillain-Barré syndrome. J. Infect. Dis., 1997, 176(2)(Suppl. 2), S125-S128.
[http://dx.doi.org/10.1086/513783] [PMID: 9396695]
[53]
Goldschmidt, B.; Menonna, J.; Fortunato, J.; Dowling, P.; Cook, S. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders. Ann. Neurol., 1980, 7(2), 108-112.
[http://dx.doi.org/10.1002/ana.410070203] [PMID: 7369715]
[54]
Jacobs, B.C.; Rothbarth, P.H.; van der Meché, F.G.; Herbrink, P.; Schmitz, P.I.; de Klerk, M.A.; van Doorn, P.A. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology, 1998, 51(4), 1110-1115.
[http://dx.doi.org/10.1212/WNL.51.4.1110] [PMID: 9781538]
[55]
Pontali, E.; Feasi, M.; Crisalli, M.P.; Cassola, G. Guillain-Barré Syndrome with fatal outcome during HIV-1-Seroconversion: a case report. Case Rep. Infect. Dis., 2011, 2011, 972096.
[http://dx.doi.org/10.1155/2011/972096] [PMID: 22567484]
[56]
Sivadon-Tardy, V.; Orlikowski, D.; Porcher, R.; Sharshar, T.; Durand, M.C.; Enouf, V.; Rozenberg, F.; Caudie, C.; Annane, D.; van der Werf, S.; Lebon, P.; Raphaël, J.C.; Gaillard, J.L.; Gault, E. Guillain-Barré syndrome and influenza virus infection. Clin. Infect. Dis., 2009, 48(1), 48-56.
[http://dx.doi.org/10.1086/594124] [PMID: 19025491]
[57]
Saxena, A. Probiotics as a potential alternative for relieving peripheral neuropathies: a case for guillain-barré syndrome. Front. Microbiol., 2016, 6, 1497.
[http://dx.doi.org/10.3389/fmicb.2015.01497] [PMID: 26779152]
[58]
Gold, R.; Hartung, H.P.; Toyka, K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today, 2000, 6(2), 88-91.
[http://dx.doi.org/10.1016/S1357-4310(99)01639-1] [PMID: 10652482]
[59]
Brooks, P.T.; Bell, J.A.; Bejcek, C.E.; Malik, A.; Mansfield, L.S. An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model. J. Neuroimmunol., 2019, 337, 577048.
[http://dx.doi.org/10.1016/j.jneuroim.2019.577048] [PMID: 31678855]
[60]
Wine, E.; Gareau, M.G.; Johnson-Henry, K.; Sherman, P.M. Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells. FEMS Microbiol. Lett., 2009, 300(1), 146-152.
[http://dx.doi.org/10.1111/j.1574-6968.2009.01781.x] [PMID: 19765084]
[61]
Sandhya, P.; Danda, D.; Sharma, D.; Scaria, V. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int. J. Rheum. Dis., 2016, 19(1), 8-20.
[http://dx.doi.org/10.1111/1756-185X.12728] [PMID: 26385261]
[62]
Abhari, K.; Shekarforoush, S.S.; Hosseinzadeh, S.; Nazifi, S.; Sajedianfard, J.; Eskandari, M.H. The effects of orally administered Bacillus coagulans and inulin on prevention and progression of rheumatoid arthritis in rats. Food Nutr. Res., 2016, 60, 30876.
[http://dx.doi.org/10.3402/fnr.v60.30876] [PMID: 27427194]
[63]
Mena-Vázquez, N.; Ruiz-Limón, P.; Moreno-Indias, I.; Manrique-Arija, S.; Tinahones, F.J.; Fernández-Nebro, A. Expansion of rare and harmful lineages is associated with established rheumatoid arthritis. J. Clin. Med., 2020, 9(4), 1044.
[http://dx.doi.org/10.3390/jcm9041044] [PMID: 32272752]
[64]
Paccou, J.; Brazier, M.; Mentaverri, R.; Kamel, S.; Fardellone, P.; Massy, Z.A. Vascular calcification in rheumatoid arthritis: prevalence, pathophysiological aspects and potential targets. Atherosclerosis, 2012, 224(2), 283-290.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.04.008] [PMID: 22703866]
[65]
Wasko, M.C.; Kay, J.; Hsia, E.C.; Rahman, M.U. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res. (Hoboken), 2011, 63(4), 512-521.
[http://dx.doi.org/10.1002/acr.20414] [PMID: 21452264]
[66]
Boers, M.; Nurmohamed, M.T.; Doelman, C.J.; Lard, L.R.; Verhoeven, A.C.; Voskuyl, A.E.; Huizinga, T.W.; van de Stadt, R.J.; Dijkmans, B.A.; van der Linden, S. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62(9), 842-845.
[http://dx.doi.org/10.1136/ard.62.9.842] [PMID: 12922956]
[67]
Giles, J.T.; Danielides, S.; Szklo, M.; Post, W.S.; Blumenthal, R.S.; Petri, M.; Schreiner, P.J.; Budoff, M.; Detrano, R.; Bathon, J.M. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol., 2015, 67(3), 626-636.
[http://dx.doi.org/10.1002/art.38986] [PMID: 25504899]
[68]
Vaghef-Mehrabany, E.; Alipour, B.; Homayouni-Rad, A.; Sharif, S.K.; Asghari-Jafarabadi, M.; Zavvari, S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition, 2014, 30(4), 430-435.
[http://dx.doi.org/10.1016/j.nut.2013.09.007] [PMID: 24355439]
[69]
Zamani, B.; Golkar, H.R.; Farshbaf, S.; Emadi-Baygi, M.; Tajabadi-Ebrahimi, M.; Jafari, P.; Akhavan, R.; Taghizadeh, M.; Memarzadeh, M.R.; Asemi, Z. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Int. J. Rheum. Dis., 2016, 19(9), 869-879.
[http://dx.doi.org/10.1111/1756-185X.12888] [PMID: 27135916]
[70]
Pineda, M. L.; Thompson, S.F.; Summers, K.; de Leon, F.; Pope, J.; Reid, G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med. Sci. Monit., 2011, 17(6), CR347-CR354.
[PMID: 21629190]
[71]
So, J.S.; Kwon, H.K.; Lee, C.G.; Yi, H.J.; Park, J.A.; Lim, S.Y.; Hwang, K.C.; Jeon, Y.H.; Im, S.H. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol. Immunol., 2008, 45(9), 2690-2699.
[http://dx.doi.org/10.1016/j.molimm.2007.12.010] [PMID: 18243320]
[72]
Hevia, A.; Milani, C.; López, P.; Cuervo, A.; Arboleya, S.; Duranti, S.; Turroni, F.; González, S.; Suárez, A.; Gueimonde, M.; Ventura, M.; Sánchez, B.; Margolles, A. Intestinal dysbiosis associated with systemic lupus erythematosus. MBio, 2014, 5(5), e01548-e14.
[http://dx.doi.org/10.1128/mBio.01548-14] [PMID: 25271284]
[73]
de la Visitación, N.; Robles-Vera, I.; Toral, M.; Duarte, J. Protective effects of probiotic consumption in cardiovascular disease in systemic lupus erythematosus. Nutrients, 2019, 11(11), 2676.
[http://dx.doi.org/10.3390/nu11112676] [PMID: 31694260]
[74]
Luo, X.M.; Edwards, M.R.; Mu, Q.; Yu, Y.; Vieson, M.D.; Reilly, C.M.; Ahmed, S.A.; Bankole, A.A. Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus. Appl. Environ. Microbiol., 2018, 84(4), 84.
[http://dx.doi.org/10.1128/AEM.02288-17] [PMID: 29196292]
[75]
Li, Y.; Wang, H.F.; Li, X.; Li, H.X.; Zhang, Q.; Zhou, H.W.; He, Y.; Li, P.; Fu, C.; Zhang, X.H.; Qiu, Y.R.; Li, J.L. Disordered intestinal microbes are associated with the activity of systemic lupus erythematosus. Clin. Sci. (Lond.), 2019, 133(7), 821-838.
[http://dx.doi.org/10.1042/CS20180841] [PMID: 30872359]
[76]
Mu, Q.; Zhang, H.; Liao, X.; Lin, K.; Liu, H.; Edwards, M.R.; Ahmed, S.A.; Yuan, R.; Li, L.; Cecere, T.E.; Branson, D.B.; Kirby, J.L.; Goswami, P.; Leeth, C.M.; Read, K.A.; Oestreich, K.J.; Vieson, M.D.; Reilly, C.M.; Luo, X.M. Control of lupus nephritis by changes of gut microbiota. Microbiome, 2017, 5(1), 73.
[http://dx.doi.org/10.1186/s40168-017-0300-8] [PMID: 28697806]
[77]
Alard, P.; Parnell, S. A.; Manirarora, J. N.; Kosiewicz, MM. Probiotics control lupus progression via induction of regulatory cells and IL-10 production. J. Immunol., 2009, 182(1), 50.30.
[78]
Gomes, A.C.; Bueno, A.A.; de Souza, R.G.; Mota, J.F. Gut microbiota, probiotics and diabetes. Nutr. J., 2014, 13, 60.
[http://dx.doi.org/10.1186/1475-2891-13-60] [PMID: 24939063]
[79]
Calcinaro, F.; Dionisi, S.; Marinaro, M.; Candeloro, P.; Bonato, V.; Marzotti, S.; Corneli, R.B.; Ferretti, E.; Gulino, A.; Grasso, F.; De Simone, C.; Di Mario, U.; Falorni, A.; Boirivant, M.; Dotta, F. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia, 2005, 48(8), 1565-1575.
[http://dx.doi.org/10.1007/s00125-005-1831-2] [PMID: 15986236]
[80]
Dolpady, J.; Sorini, C.; Di Pietro, C.; Cosorich, I.; Ferrarese, R.; Saita, D.; Clementi, M.; Canducci, F.; Falcone, M. Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment. J. Diabetes Res., 2016, 2016, 7569431.
[http://dx.doi.org/10.1155/2016/7569431] [PMID: 26779542]
[81]
Uusitalo, U.; Liu, X.; Yang, J.; Aronsson, C.A.; Hummel, S.; Butterworth, M.; Lernmark, Å.; Rewers, M.; Hagopian, W.; She, J.X.; Simell, O.; Toppari, J.; Ziegler, A.G.; Akolkar, B.; Krischer, J.; Norris, J.M.; Virtanen, S.M. TEDDY Study group. association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr., 2016, 170(1), 20-28.
[http://dx.doi.org/10.1001/jamapediatrics.2015.2757] [PMID: 26552054]
[82]
Kim, J.; Choi, S.H.; Kim, Y.J.; Jeong, H.J.; Ryu, J.S.; Lee, H.J.; Kim, T.W. Im, S.H.; Oh, J.Y.; Kim, M.K. Clinical Effect of IRT-5 probiotics on immune modulation of autoimmunity or alloimmunity in the eye. Nutrients, 2017, 9(11), 1166.
[http://dx.doi.org/10.3390/nu9111166]
[83]
Choi, S.H.; Oh, J.W.; Ryu, J.S.; Kim, H.M. IRT5 Probiotics changes immune modulatory protein expression in the extraorbital lacrimal glands of an autoimmune dry eye mouse model. Investig. Opthalmology Vis. Sci., 2020, 61, 42.
[84]
Xie, W.R.; Yang, X.Y.; Xia, H.H.; Wu, L.H.; He, X.X. Hair regrowth following fecal microbiota transplantation in an elderly patient with alopecia areata: A case report and review of the literature. World J. Clin. Cases, 2019, 7(19), 3074-3081.
[http://dx.doi.org/10.12998/wjcc.v7.i19.3074] [PMID: 31624757]
[85]
Kalliomäki, M.; Salminen, S.; Arvilommi, H.; Kero, P.; Koskinen, P.; Isolauri, E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet, 2001, 357(9262), 1076-1079.
[http://dx.doi.org/10.1016/S0140-6736(00)04259-8] [PMID: 11297958]
[86]
Kalliomäki, M.; Salminen, S.; Poussa, T.; Arvilommi, H.; Isolauri, E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet, 2003, 361(9372), 1869-1871.
[http://dx.doi.org/10.1016/S0140-6736(03)13490-3] [PMID: 12788576]

Rights & Permissions Print Cite
Article Metrics
55
2
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy